Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment

Reuters

Feb 10

Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment

Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema $(HAE)$ attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651761-en) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610644910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610644910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610644910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610644910","market":"us","top_or_hot":-1,"title":"Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) 2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651761-en) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) 2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651761-en) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHVS","symbol_name":"Pharvaris N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL1Q9GYl:1","article_id":"2610644910","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610644910","pubTimestamp":1770724218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma & Immunology  2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema  attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHVS":"Pharvaris N.V.","NDAQ":"纳斯达克OMX交易所","BK4007":"制药","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Pharvaris公布Deucrictibant治疗HAE的积极3期RAPIDe-3数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":0.9,"NDAQ":0.9},"content_text":"Pharvaris Unveils Positive Phase 3 RAPIDe-3 Data for Deucrictibant in HAE Treatment\n    \n\n        Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema $(HAE)$ attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651761-en) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}